Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Meningococcal Group ACYW135 Conjugate Vaccine
NCT04236960Phase 1Completed
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Meningococcal group ACYW135 conjugate vaccine in meningococcal infection (5 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoint: Incidence of adverse events. Started Jul 2018; status: completed.
02
Drugs
Meningococcal group ACYW135 conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT04236960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236960.